Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
The primary objective of this study is the proof of mechanism and support of dose finding,
 together with the safety evaluation in patients with clinical evidence of NASH.

 To gain further insight into clinical effects of AOC3 inhibition on NASH further exploratory
 analyses of biomarkers related to NASH and liver fibrosis will be performed. This will
 include the effect of BI 1467335 on reduction of secondary biomarker endpoints (ALT, AST, AP,
 γ-GT and CK18 fragments). Safety will be assessed throughout the study to provide key
 information regarding the use of BI 1467335 in patients with NASH.
Inclusion criteria:

 -  Clinical evidence of NASH defined as a. histological evidence of NASH (no more than 3
 years prior to screening) OR b. clinical imaging results suggestive of NASH (no more
 than 3 years prior to screening) OR within the screening phase, imaging procedures
 performed as per local standard) i. evidence of hepatic steatosis >5% measured by the
 MRI-PDFF) or assessed as moderate to severe steatosis (raised echogenicity of the
 liver parenchyma) by ultrasound AND ii. evidence of liver fibrosis defined as mean
 stiffness > 3.64 kPa as measured by the MRE protocol or mean stiffness > 7.2 kPa as
 measured by ultrasound based transient elastography (Fibroscan®)

 -  Increased ALT defined as a. ALT >1.5 ULN at screening and ALT >1.25 ULN in a local lab
 within 1 week to 3 months prior screening OR b. Historic ALT > 1.25 ULN more than 3
 months prior to screening and two consecutive ALT > 1.5xULN must be confirmed at least
 1 week apart within the screening period

 -  Age ≥ 18 and ≤75 years at screening

 -  BMI ≥25kg/m2 and <45kg/m2 at screening

 -  Stable body weight defined as less than 5% change in body weight in the 3 months prior
 to screening while being treated with the standard of care and not treated with
 anti-obesity medication at screening.

 -  Treatment with Antidiabetic concomitant medication including any insulin regimen needs
 to be stable for 3 months, and treatment with vitamin E needs to be stable for 6
 months prior to informed consent and expected to be stable throughout the trial. All
 other concomitant medication has to be stable for at least 4 weeks prior screening.
 Concomitant medications taken to treat acute conditions (e.g. headache, sinusitis) for
 a short period (< 7 days) are permissible, if not otherwise prohibited.

 -  For female patients: Women of childbearing potential* can be randomized after a
 negative pregnancy test and under adequate contraception with two methods, of which at
 least one is highly effective, during the trial.* A woman is considered of
 childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming
 post-menopausal unless permanently sterile. Permanent sterilisation methods include
 hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is
 NOT a method of permanent sterilisation. A postmenopausal state is defined as no
 menses for 12 months without an alternative medical cause.

 -  Signed and dated written informed consent in accordance with GCP and local legislation
 prior to admission to the trial.

 Exclusion criteria:

 -  Current or history of significant alcohol consumption (defined as intake of >210g/week
 in males and >140g/week in females on average over a consecutive period of more than 3
 months) or inability to reliably quantify alcohol consumption based on investigator
 judgement.

 -  Prior participation in an interventional NASH trial 6 months before baseline or 5
 times halflife of the investigational drug, whichever is longer.

 -  Prior or planned bariatric surgery during study conduct, except gastric-band surgery
 more than 2 years prior to screening (including adjustments) with a stable body weight
 within the last 12 months.

 -  Use of drugs historically associated with liver injury, hepatic steatosis or
 steatohepatitis in the 4 weeks prior to screening.

 -  History of liver cirrhosis (fibrosis stage 4), or hepatic decompensation (e.g.
 ascites, hepatic encephalopathy, variceal bleeding, etc.) or history of other forms of
 chronic liver disease (for example Hepatitis B, Hepatitis C, autoimmune liver disease,
 primary biliary sclerosis, primary sclerosing cholangitis, Wilsons disease,
 hemochromatosis, A1At deficiency, history of liver transplantation).

 -  Active known chronic or relevant acute infections, such as HIV (Human Immunodeficiency
 Virus), \viral hepatitis, or tuberculosis. QuantiFERON® TB test and HBs Ag test will
 be performed during screening. Patients with a positive test result may participate in
 the study if further work up (according to local practice/guidelines) establishes
 conclusively that the patient has no evidence of active infection.

 -  Solid liver lesions other than haemangiomas.

 -- Suspicion or diagnosis or history of hepatocellular carcinoma (HCC)

 -  eGFR <60ml/min/1.73m2 at screening (CKD-EPI formula).

 -  ALT >5.0 ULN at screening.

 -  Platelet count < 150.000/μL

 -  Bilirubin level > ULN (except for known Gilbert´s disease with a conjugated bilirubin
 of < 0.3 mg/dL))

 -  Uncontrolled diabetes defined as an HbA1c ≥9.5% in the 3 months prior to or at
 screening.

 -  Diagnosis of a serious or unstable disease including hepatic (other than NASH), renal,
 gastroenterologic, respiratory, cardiovascular (including ischemic heart disease),
 endocrinologic, neurologic , psychiatric, immunologic, or hematologic disease and
 other conditions that, in the clinical judgment of the investigator, are likely to
 interfere with the analyses of safety and efficacy in this study. Patients with an
 expected life expectancy of less than 2 years are also excluded.

 -  Major surgery (major according to the investigator's assessment) performed within 12
 weeks prior to randomisation or planned during study conduct, e.g. hip replacement.

 -  Any documented active or suspected malignancy or history of malignancy within 5 years
 prior to screening, except appropriately treated basal cell carcinoma of the skin or
 in situ carcinoma of uterine cervix.

 -  Patients who must or wish to continue the intake of restricted medications or any drug
 considered likely to interfere with the safe conduct of the trial.

 -  Previous randomisation in this trial.

 -  Currently enrolled in another investigational device or drug study, or less than 30
 days since ending another investigational device or drug study(s), or receiving other
 investigational treatment(s).

 -  Chronic drug abuse or any condition that, in the investigator's opinion, makes them an
 unreliable study subject or unlikely to complete the trial.

 -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

 -  Patients with Wolff-Parkinson-White Syndrome, baseline QTc > 450 ms, family history of
 long QT, or on medication prolonging QT time at screening or planned initiation during
 the trial.

 -  Any other clinical condition that, in the opinion of the investigator, would
 jeopardize patient safety while participating in this clinical trial.